Share Price, page-10747

I am far from an expert, but I suspect the company has already completed what it needs to do for pre-clinical work. I think the meeting with the FDA for Phase 3 design for Phelan McDermid Syndrome is the one of the most important milestones but because it affects a lot of other designs and how additional Phase 2 trials will be run. I suspect they won't make the additional indications known publicly until all the groundwork for those Phase 2 trials have been done (and this happens after discussing what they need to in terms of safety profile with the FDA). My guess is by Q4 of this calendar year. By then we'll know the trial design and what the FDA wants for P3 and how the improved protocol can be applied to Angelman + the other indications.